Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

    Ruchi Mathur, О С Левин, Ricardo Azziz
    TLDR The birth control combination of ethinylestradiol and drospirenone helps treat symptoms of polycystic ovary syndrome.
    The document discusses the use of combined oral contraceptive (COC) therapy, specifically the ethinylestradiol/drospirenone combination, in treating women with polycystic ovary syndrome (PCOS), which affects approximately 105 million women globally. COC therapy is highlighted as a key treatment for PCOS symptoms such as excessive hair growth, irregular menstruation, acne, and weight gain. The paper emphasizes the importance of selecting an appropriate progestin to maximize antiandrogenic effects, noting that drospirenone, a newer progestin, has been beneficial for women with PCOS when combined with ethinyl estradiol. Additionally, the document mentions that there is controversy surrounding the metabolic effects of COCs in PCOS patients.
    View this study on dovepress.com →

    Cited in this study

    Related

      Hyperandrogenism in Women: Polycystic Ovary Syndrome

      research Hyperandrogenism in Women: Polycystic Ovary Syndrome

      3 citations ,   January 2012 in “Hanyang Medical Reviews”
      The document concludes that more research is needed to create suitable diagnostic criteria and understand PCOS in Korean women, and genetics may allow for personalized treatment.
      Diagnosis of hyperandrogenism: clinical criteria

      research Diagnosis of hyperandrogenism: clinical criteria

      85 citations ,   June 2006 in “Best Practice & Research Clinical Endocrinology & Metabolism”
      The document concludes that hirsutism is the main sign for diagnosing hyperandrogenism, which requires a detailed patient history and physical exam.